Artificial intelligence (AI) is revolutionising industries. But with this exciting new frontier comes a complex challenge: protecting your intellectual property (IP).
It is essential for healthcare and pharmaceutical companies to be aware of both critical and non-critical risks when conducting quality clinical trials.
Are you prepared for the upcoming changeover to the new EU risk management plan (RMP) template? Seema Jaitly offers some timely guidance on the new EU RMP document.
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.